Is Arcus‑BMS Kidney Cancer Collaboration Altering The Investment Case For Arcus Biosciences (RCUS)?

• In late May 2026, Arcus Biosciences announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate its HIF-2α inhibitor casdatifan in combination with BMS’s bispecific T‑cell engager pumitamig in the BMS-sponsored Phase 1/2 ROSETTA RCC‑208 study for advanced renal cell carcinoma.
• This collaboration adds new casdatifan-based arms to an existing BMS kidney cancer trial, potentially broadening Arcus’s clinical footprint in TKI‑free treatment approaches and combination regimens.
• We’ll now examine how adding casdatifan to Bristol Myers Squibb’s ROSETTA RCC‑208 trial could reshape Arcus Biosciences’ kidney cancer investment narrative.

Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

Arcus Biosciences Investment Narrative Recap

To own Arcus Biosciences, you have to believe its oncology pipeline, especially HIF‑2α inhibitor casdatifan, can translate promising data into approved, commercially relevant drugs despite ongoing losses and trial setbacks. The new Bristol Myers Squibb collaboration expands casdatifan’s presence in kidney cancer and could reinforce its role in the key RCC program, but it does not meaningfully change the near term regulatory and clinical risk around dom‑zim and casdatifan.

Among recent developments, the April 2026 discontinuation of the STAR‑121 lung cancer trial is most relevant, as it sharpened Arcus’s focus on casdatifan and other priority programs. That setback heightened execution and funding risks tied to a narrower portfolio, which makes the new BMS‑run ROSETTA RCC‑208 casdatifan combination arms especially important as a validation point for Arcus’s kidney cancer strategy.

Yet, against the promise of new kidney cancer combinations, investors should also be aware that regulatory uncertainty around dom‑zim and casdatifan could...

Read the full narrative on Arcus Biosciences (it's free!)

Arcus Biosciences' narrative projects $238.4 million revenue and $45.1 million earnings by 2029. This implies fairly flat yearly revenue growth and a $414.1 million earnings increase from -$369.0 million today.

Uncover how Arcus Biosciences' forecasts yield a $34.82 fair value, a 46% upside to its current price.

Exploring Other Perspectives

Before this collaboration, the most optimistic analysts were already assuming roughly 36 percent annual revenue growth to about US$624.5 million by 2029, so if you believe casdatifan could truly reduce dependency on partner revenue, this news might eventually push that bullish narrative even further than the current consensus allows.

Explore 3 other fair value estimates on Arcus Biosciences - why the stock might be worth over 7x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Arcus Biosciences research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Arcus Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Arcus Biosciences' overall financial health at a glance.

No Opportunity In Arcus Biosciences?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 13 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Rare earth metals are the new gold rush. Find out which 32 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com